Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Single Dose Ponesimod in Healthy Japanese and Caucasian Subjects
NCT02223832Phase 1Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Feb 2009
- Primary completion
- Apr 2009
- Modality
- Covalent Small Molecules, Molecular Glues, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ponesimod in multiple sclerosis (MS), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Change in systolic blood pressure up to 10 days, Change in diastolic blood pressure up to 10 days and 9 more. Started Feb 2009; status: completed.
02
Drugs
ponesimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02223832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02223832.